TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19915480
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg + Haloperidol 1.5 mg
Study: 19915480
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg + Placebo
Study: 17975386
Drug: Standard timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard timing of renal replacement therapy
Study: 16249547
Drug: Pitavastatin 1
Normalized name: PITAVASTATIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 1 mg/day for 12 months (group B1)
Study: 11844826
Drug: Vorozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole (2.5 mg per day for 12 weeks)
Study: 11844826
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg per day for 12 weeks)
Study: 2104074
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (500 mg t.d.s.)
Study: 24398053
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg once daily at bedtime
Study: 19463030
Drug: Psychoeducational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational music therapy
Study: 8212823
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose given to 34 children with anti-HBs titres lower or slightly higher than 100 IU l‐1
Study: 23364004
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (10 μg vitamin D(3)/d and 1.2 g Ca/d, with 375 μg weekly)
Study: 23364004
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent to 63 μg (2500 IU)/d and 10 μg (400 IU)/d)
Study: 16160867
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.4 IU/kg)
Study: 16734552
Drug: Insulin ultralente
Normalized name: INSULIN ULTRALENTE BEEF 100 U/ML IJ NOVO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin ultralente
Study: 16734552
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.3 IU/kg)
Study: 16734552
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (tailor-made dose)
Study: 2423408
Drug: Amylase inhibitor
Normalized name: amylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylase inhibitor
Study: 20545217
Drug: 0.0015% tafluprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0015% tafluprost ophthalmic solution
Study: 16619567
Drug: PS76A2 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS76A2 (15 ng mistletoe lectin/0.5 ml)
Study: 12746765
Drug: Fluconazole plus
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole plus placebo (800 mg per day)
Study: 12746765
Drug: Fluconazole plus
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole plus amphotericin B (0.7 mg/kg per day for the first 5-6 days)
Study: 7531023
Drug: Electrochemical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemical therapy (ECT) with systemic chemotherapy
Study: 7531023
Drug: Electrochemical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrochemical therapy (ECT) alone
Study: 7531023
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (systemic chemotherapy alone)
Study: 3279010
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg orally four times a day for 2 weeks)
Study: 23649964
Drug: Brivaracetam 100
Normalized name: brivaracetam 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 100 mg single oral dose in participants with mild hepatic impairment
Study: 23649964
Drug: Brivaracetam 100
Normalized name: brivaracetam 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 100 mg single oral dose in participants with moderate hepatic impairment
Study: 23649964
Drug: Brivaracetam 100
Normalized name: brivaracetam 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 100 mg single oral dose in participants with severe hepatic impairment
Study: 23649964
Drug: Brivaracetam 100
Normalized name: brivaracetam 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 100 mg single oral dose in healthy controls
Study: 23649964
Drug: Brivaracetam metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam metabolism in hepatic impairment
Study: 22191234
Drug: Phototherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapeutic treatment in addition to standard radio- and hormonal therapy (n=308)
Study: 22191234
Drug: Standard radio-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radio- and hormonal therapy alone (n=251)
Study: 19088057
Drug: Eccentric loading
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric loading plus shock-wave treatment
Study: 17452150
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of pioglitazone
Study: 15284252
Drug: Irinotecan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan treatment continued until disease progression (n = 25)
Study: 15284252
Drug: Irinotecan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan treatment stopped after 8 cycles (n = 30)
Study: 9754822
Drug: Linomide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linomide 2.5 mg
Study: 2191485
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy (rt-PA)
Study: 679080
Drug: Oral neomycin
Normalized name: neomycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neomycin and erythromycin base preoperatively
Study: 31842026
Drug: Doxapram 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 1 mg/kg ideal body weight
Study: 21710401
Drug: Second-Generation Antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-Generation Antipsychotics (SGAs)
Study: 21710401
Drug: Drug company
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug company representatives as information source
Study: 16001181
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/day plus calcium 1,000 mg/day and vitamin D 800 IU/day
Study: 16001181
Drug: Control (alfacalcidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (alfacalcidol 1 mug/day plus calcium 500 mg/day or vitamin D 1,000 IU/day plus calcium 800 mg/day)
Study: 15167985
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (10 min/day for 6 months)
Study: 7534945
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Enoxaparin and Dextran
Study: 3655512
Drug: Lateral subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral subcutaneous sphincterotomy
Study: 26839889
Drug: MDI4 (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI4 (four injections daily, glargine based)
Study: 26839889
Drug: MDI3 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI3 (three injections daily, aspart 30-based)
Study: 24730050
Drug: Aerosolized albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized albuterol (5mg q4h)
Study: 22687231
Drug: Higher numbers
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher numbers of drugs prescribed during follow-up
Study: 19248655
Drug: MA 60
Normalized name: Drizalma 60 MG Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 60 mg/kg/day/ IM and oral placebo for three weeks
Study: 19248655
Drug: MA 30
Normalized name: Lasma 300 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 30 mg/kg/day/IM and oral omeprazole 40 mg/day for three weeks
Study: 19248655
Drug: MA 30
Normalized name: Lasma 300 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 30 mg/kg/day/IM and oral placebo for three weeks
Study: 10629357
Drug: eptastigmine 10
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eptastigmine 10 mg t.i.d. and 12 mg t.i.d. for 25 weeks
Study: 6827407
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (53 children)
Study: 6827407
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group (128 children)
Study: 31123008
Drug: Amoxicillin 70-90
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 70-90 mg/kg/day for 3 or 7 days
Study: 31123008
Drug: Amoxicillin 35-50
Normalized name: amoxicillin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 35-50 mg/kg/day for 3 or 7 days
Study: 31123008
Drug: Amoxicillin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (both dosages)
Study: 22002249
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment (simple, low-cost environmental modifications)
Study: 22002249
Drug: Intense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense treatment (added elements to engage management)
Study: 22002249
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment conditions (moderate vs. intense)
Study: 17325603
Drug: Nonnucleoside reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonnucleoside reverse transcriptase inhibitor (NNRTI)
Study: 17325603
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor + Nonnucleoside reverse transcriptase inhibitor (PI + NNRTI)
Study: 11449531
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 800 micrograms/daily
Study: 11449531
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 840 micrograms/daily
Study: 9684692
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) administered before meals
Study: 9684692
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) administered during meals
Study: 7511495
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin (5% albumin solution)
Study: 2894751
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) infusion (20 mU/kg/h)
Study: 20052461
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg etoricoxib (n = 8)
Study: 17117227
Drug: Intrapericardial triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapericardial triamcinolone hexacetonide 200 mg
Study: 17117227
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone plus intrapericardial placebo
Study: 14664167
Drug: Arifon retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arifon retard monotherapy
Study: 14664167
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of arifon retard and climonorm
Study: 14664167
Drug: Arifon retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arifon retard in combination with climonorm
Study: 10655249
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin levels in women
Study: 10655249
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin and C-peptide in men
Study: 1338389
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg once daily for 24 weeks
Study: 6711261
Drug: suxamethonium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.1 mg/kg
Study: 27322462
Drug: 5mg finasteride
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg finasteride daily for 4-6 weeks
Study: 20416389
Drug: Inhaled magnesium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled magnesium sulfate (333 mg in 3 ml solution)
Study: 20416389
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 ml isotonic saline solution with albuterol and ipratropium)
Study: 17700289
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of M‐FDT with the latter pair of criteria
Study: 10730980
Drug: PGF2alpha treatment
Normalized name: PGF2alpha THAM
DrugBank: Dinoprost tromethamine (DB01160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2alpha treatment
Study: 10730980
Drug: Progesterone treatment
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone treatment (100 mg daily from Days 10 to 30)
Study: 8803525
Drug: S-1452 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1452 (50 mg) with food
Study: 8803525
Drug: S-1452 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1452 (50 mg) without food
Study: 8803525
Drug: S-1452 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1452 (50 mg) with food and without food
Study: 28489511
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg twice per day)
Study: 23187951
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of β‐glucans daily for 8 weeks
Study: 21489769
Drug: Bupivacaine 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.625 mg/mL with epinephrine 5 μg/mL at 10 mL/hr
Study: 21489769
Drug: Bupivacaine 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.625 mg/mL at 10 mL/hr
Study: 19069713
Drug: Perineural injection
Normalized name: ROPIVACAINE HYDROCHLORIDE 2 mg in 1 mL PERINEURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural injection of 1 ml of betamethasone after surgical decompression
Study: 3913752
Drug: L-5-Hydroxytryptophan (L-5-HTP)
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-Hydroxytryptophan (L-5-HTP)
Study: 29533686
Drug: MIES (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIES (all doses)
Study: 30427213
Drug: Standard cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive‐behavioral therapy (CBT)
Study: 26970721
Drug: LAM-guided anti-tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM-guided anti-tuberculosis treatment initiation
Study: 24524676
Drug: CNS stimulants
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS stimulants (methylphenidate or dexamphetamine)
Study: 29154553
Drug: Female‐Specific Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female‐Specific Cognitive Behavioral Therapy (FS‐CBT)
Study: 30831454
Drug: Paliperidone-extended release
Normalized name: paliperidone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone-extended release formulation
Study: 27609242
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment (open group)
Study: 27609242
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (placebo-controlled group)
Study: 19216655
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions)
Study: 17990836
Drug: Long-acting inhaled
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting inhaled anticholinergics
Study: 17990836
Drug: Long-acting inhaled
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting inhaled anticholinergics, inhaled corticosteroids, possibly long-acting beta2 agonist or mucolytics
Study: 17990836
Drug: Short-acting beta2
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta2 agonists or combination anticholinergics with a short-acting beta2 agonist
Study: 23668549
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg)
Study: 7658874
Drug: Bosentan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (100 mg followed after 60 min by 200 mg)
Study: 1089090
Drug: Marijuana smoking
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana smoking (12 mg delta9‐tetrahydrocannabinol)
Study: 22689129
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of POMx
Study: 22689129
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of POMx
Study: 18804874
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly water exercise (60 minutes, 1 session per week for 2 years)
Study: 18804874
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly water exercise (60 minutes, 2 sessions per week for 2 years)
Study: 10370793
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 by three-hour infusion on day 1 and gemcitabine 1100 mg/m2 over 30 min on days 1 and 8, repeated every three weeks for six cycles.
Study: 93982
Drug: Crossover therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover therapy with 5-FU alone
Study: 19390239
Drug: Pranlukast hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast hydrate plus oral mequitazine
Study: 19390239
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride plus oral mequitazine
Study: 14742342
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of rocuronium
Study: 8557012
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of rocuronium
Study: 9164208
Drug: Paclitaxel 150
Normalized name: paclitaxel 150 MG per 25 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 150 mg/m2
Study: 9164208
Drug: Paclitaxel 275
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 275 mg/m2
Study: 27108672
Drug: lurasidone 40
Normalized name: lurasidone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: lurasidone 40 mg
Study: 25470096
Drug: RUL brief‐pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUL brief‐pulse ECT (mean dose = 233.3 mC)
Study: 25470096
Drug: Algorithm‐based pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm‐based pharmacologic treatment (APT)
Study: 22826463
Drug: [(14)C]β‐sitosterol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(14)C]β‐sitosterol administered orally
Study: 22826463
Drug: [(14)C]β‐sitosterol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(14)C]β‐sitosterol administered intravenously
Study: 11910264
Drug: 5-HTP 200
Normalized name: 5-HTP 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HTP 200 mg
Study: 12534636
Drug: Ropivacaine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 50 mg, 100 mg, and 200 mg base as 20-ml gel enemas
Study: 1621138
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (classical tranquilizers)
Study: 30700475
Drug: Standard sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sequential chemoradiotherapy schedule of 55 Gy in 20 fractions over 4 weeks
Study: 30700475
Drug: Experimental radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental radiotherapy schedules (4 separate dose escalation accelerated radiotherapy schedules)
Study: 27362935
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of anti-CD138-IFNα14 and bortezomib
Study: 17372173
Drug: hs-CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP levels 1 to 3 mg/L
Study: 17372173
Drug: hs-CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP levels >3 mg/L
Study: 776350
Drug: Methyldopa 750
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa 750 mg/day combined with propranolol 240 mg/day
Study: 776350
Drug: Methyldopa 750
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa 750 mg/day combined with practolol 600 mg/day